Another study showed a significant difference in the SPARC levels in tumor tissue between gastric cancer and ESCC (15% vs. 34%) [37], suggesting SPARC as a potential novel therapeutic target. This evidence concerns the gene SPARC and esophageal squamous cell carcinoma.